BR MP01
Alternative Names: BR-MP01Latest Information Update: 25 Aug 2023
At a glance
- Originator BlueRock Therapeutics
- Class Antineoplastics; Gene therapies; Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 31 Jul 2023 Preclinical trials in Solid tumours in USA (Parenteral) prior to July 2023 (BlueRock Therapeutics pipeline, July 2023)